Skonec and Dragonfly Begin Joint Development of "Guardians DTx" for ADHD Treatment

On May 12, Skonec Entertainment, a company specializing in XR (Extended Reality) content, announced that it will officially begin joint development of "Guardians DTx" (tentative name), a digital therapeutic device for ADHD (Attention Deficit Hyperactivity Disorder) treatment, in partnership with Dragonfly, the developer of the FPS game "Special Force." The two companies are building a next-generation digital therapeutic platform that combines game-based therapeutic content with immersive XR technology, aiming for a strategic entry into the medical and healthcare markets.

"Guardians DTx" primarily targets children aged 7 and above but under 13 who have been diagnosed with ADHD. The device features gamified content based on cognitive behavioral therapy (CBT), including modules for enhancing attention, impulse control, and sustained cognitive training. The platform goes beyond a simple game format, featuring a self-regulation therapeutic structure that induces sensory stimulation and response training within a VR immersive environment. In this collaboration, Skonec is responsible for content design, UX development, interaction engine, and overall device platform design, while Dragonfly leads the development of game-based therapeutic content and clinical linkage for children with ADHD.

The two companies, in cooperation with Pusan National University Hospital and the Pusan National University Industry-University Cooperation Foundation, completed an exploratory clinical trial in the fourth quarter of last year. This year, they plan to conduct confirmatory clinical trials and proceed with the Korea Food and Drug Administration (KFDA) medical device certification process simultaneously. In addition, through technological collaboration with the AI specialist company Selvas AI, they will further advance precision digital therapeutic functions such as treatment response analysis algorithms and user-customized feedback systems. By the first half of 2026, they plan to complete domestic medical device certification and review insurance reimbursement strategies, and from the second half, they aim to enter the global market, including applying for FDA DTx certification in the United States.

The CEO of Skonec stated, "Based on XR technology that has been proven in education, military, and safety training, we are expanding into the digital healthcare field through this project," adding, "Guardians DTx is not just software but 'therapeutic content,' and it will serve as a real turning point where technology contributes to human health."

The CEO of Dragonfly said, "Children with ADHD face the burden of repeated medication, but game-based digital therapy can help alleviate symptoms in an immersive environment without side effects. Through our collaboration with Skonec, we will dramatically enhance the quality and immersion of therapeutic content."

This project, which fuses gaming, XR technology, and medical content, is expected to provide a non-pharmaceutical solution to ADHD, a representative neurodevelopmental disorder, while also serving as a milestone that highlights the public value of the gaming industry. The two companies plan to expand their connections with domestic and international medical institutions and insurance markets by aligning with the government's digital therapeutics certification framework and K-healthcare export strategies. In particular, the ADHD digital therapeutics market is expected to grow to $20 billion by 2028, and "Guardians DTx" is drawing attention as the first domestically developed commercial model with the potential to lead the global game-based DTx market.